Atlas Molecular Pharma has a flexible approach to, and interests regarding, business development including licensing of assets for specific projects through to broader collaborations/alliances.
If you have a potential interest in our lead Congenital Erythropoietic Porphyria project or other activities please contact us.
Our current focus is to discover a new and effective treatment for patients living with CEP. We have discovered initial compounds which stabilise a key enzyme, whose activity is significantly reduced, in CEP and increase its activity towards normal levels. Further activities will be aimed at optimising these potential drugs to allow us to evaluate their effects in clinical trials with the help of a larger Company/Partner.
We believe your input will help us design a treatment that affects the key aspects of your disease, as well as providing significant insight and advocacy in interactions with Regulatory Authorities and potential Partners who will help us get the treatment to the market and to you, the patient. If you have CEP or are a family member of a CEP patient and have any questions, or would like to become involved with us to help us successfully deliver a much-needed treatment, please contact us.